Biopharma’s ballooning licensing deal bill

Surging valuations have been a feature of life for biopharma for some time now, prompting concerns that high prices could hold back deal making. However, little evidence of a slowdown can be seen in licensing transactions, and the cost of sealing these deals has actually been rising.